146
Participants
Start Date
January 24, 2018
Primary Completion Date
March 18, 2019
Study Completion Date
March 18, 2019
NLA101
"NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use."
Standard of Care (SOC) chemotherapy
The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
St. Vincent's Hospital Sydney, Darlinghurst
St. George Hospital, Kogarah
Calvary Mater Newcastle, Waratah
Austin Health, Heidelberg
Epworth HealthCare, Richmond
Royal Adelaide Hospital, Adelaide
Royal Perth Hospital, Perth
Weill Cornell Medical College - NewYork-Presbyterian Hospital, New York
Icahn School of Medicine at Mount Sinai and Mount Sinai Health System, New York
Memorial Sloan Kettering Cancer Center, New York
Westchester Medical Center, Hawthorne
Stony Brook University, Stony Brook
West Penn Hospital, Pittsburgh
Geisinger Medical Center, Danville
Gachon University Gil Medical Center, Incheon
Wake Forest Baptist Health, Winston-Salem
Duke University Heath System, Duke Cancer Center, Durham
Winship Cancer Institute, Emory University, Atlanta
Mayo Clinic Florida, Jacksonville
Norton Cancer Institute, St. Matthews Campus, Louisville
Froedtert Hospital and The Medical College of Wisconsin, Milwaukee
University of Wisconsin, Madison
Mayo Clinic, Rochester
Loyola University Medical Center, Maywood
University of Chicago Medical Center, Chicago
University of Nebraska Medical Center - Fred & Pamela Buffett Cancer Center, Omaha
The University of Texas MD Anderson Cancer Center, Houston
USC Norris Comprehensive Cancer Center, Los Angeles
UC San Diego Moores Cancer Center, La Jolla
University of California Davis Comprehensive Cancer Center, Sacramento
Swedish Cancer Institute, Seattle
Seattle Cancer Care Alliance, Seattle
Massachusetts General Hospital, Boston
Seoul National University Hospital, Seoul
Samsung Medical Center, Seoul
The Catholic University of Korea's Seoul St. Mary's Hospital, Seoul
Lead Sponsor
Nohla Therapeutics, Inc.
INDUSTRY